Press Releases
Press Release filters
Sign up to receive updates from mdxhealth
Click the button below to fill in your contact information and receive updates from mdxhealth.
MDxHealth Presents Results from Epigenetic Test to Identify Prostate Cancer Aggressiveness at the European Association of Urology Meeting 2014
IRVINE, CA, and HERSTAL, BELGIUM – October 7, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company th
MDxHealth’s ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
Company initiates enrollment into prospective PASCUAL clinical utility trial IRVINE, California, and HERSTAL, BELGIUM – September
MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
IRVINE, California, and HERSTAL, BELGIUM – September 8, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic
MDxHealth Reports First Half Year 2014 Results
Strong market adoption leads to more than doubling of ConfirmMDx case volume IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2014 –
MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
Validation Study Data Published in The Journal of Urology® IRVINE, California, and HERSTAL, BELGIUM – August 18, 2014 – MDxHealt
MDxHealth Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
Agreements add more than 4.5 million insured lives IRVINE, CA, and HERSTAL, BELGIUM – August 14, 2014 MDxHealth SA (NYSE Euronext
MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
The Centers for Medicare & Medicaid Services issues a preliminary decision to cover the cost of the test IRVINE, CA, and HERS
MDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM – July 2, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that
MDxHealth : Extraordinary General Shareholders’ Meeting
IRVINE, CA, and HERSTAL, BELGIUM, 23 June 2014 -MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that de
ConfirmMDx Draft Medicare Coverage Policy Posted for Public Comment
IRVINE, California, and HERSTAL, BELGIUM – June 20, 2014 – MDxHealth SA (NYSE Euronext: MDXH), today announced that a draft covera
MDxHealth Shareholder Transparency Notification
IRVINE, CA, and HERSTAL, BELGIUM, June 17th, 2014 -MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that
MDxHealth’s Annual and Extraordinary General Shareholders’ Meeting
IRVINE, CA, and HERSTAL, BELGIUM, 30 May, 2014 -MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that de
MDxHealth Reports 10-Fold Reduction of Repeat Prostate Biopsies in ConfirmMDx Clinical Utility Study
Results Published in American Health and Drug Benefits IRVINE, CA, and HERSTAL, BELGIUM – May 20, 2014 – MDxHealth SA (NYSE Eurone
MDxHealth Announces Presentations on ConfirmMDx for Prostate Cancer at American Urological Association 2014 Annual Meeting
IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that
MDxHealth and American Pathology Partners Announce Marketing Agreement for ConfirmMDx for Prostate Cancer
IRVINE, CA, and LIEGE, BELGIUM – May 13, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that de
MDxHealth’s ConfirmMDx DOCUMENT Validation Study Published in the Journal of Urology
ConfirmMDx is Most Significant Independent Predictor for Prostate Cancer in a Repeat Biopsy IRVINE, CA, and HERSTAL, BEL
MDxHealth Provides First Quarter 2014 Business Update
ConfirmMDx Test Volume Increases 257% over First Quarter 2013 IRVINE, CA, and HERSTAL, BELGIUM – May 6, 2014 – MDxHealth SA (NYSE
MDxHealth Signs Agreement with Galaxy Health Network PPO Providing Increased Access to ConfirmMDx for Prostate Cancer
Agreement Increases Access with Additional 3.5 Million Covered Lives IRVINE, CA, and HERSTAL, BELGIUM — 8:00 AM, April 22, 2014
MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM – April 2, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that
MDxHealth Licensee Exact Sciences Receives FDA Panel Recommendation for Approval of Colorectal Cancer Screening Test
MDxHealth’s Epigenetic Biomarker Used in Cologuard Test IRVINE, CA, and HERSTAL, BELGIUM – March 28, 2014 – MDxHealth SA (NYSE Eu
